PortfoliosLab logoPortfoliosLab logo
PBE vs. XLV
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

PBE vs. XLV - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Invesco Dynamic Biotechnology & Genome ETF (PBE) and State Street Health Care Select Sector SPDR ETF (XLV). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, PBE achieves a 10.26% return, which is significantly higher than XLV's 5.90% return. Over the past 10 years, PBE has underperformed XLV with an annualized return of 8.19%, while XLV has yielded a comparatively higher 9.81% annualized return.


PBE

1D
-1.64%
1M
-2.64%
6M
10.64%
YTD
10.26%
1Y
39.36%
3Y*
13.77%
5Y*
3.98%
10Y*
8.19%
ALL TIME*
9.16%

XLV

1D
-0.59%
1M
-0.73%
6M
5.94%
YTD
5.90%
1Y
26.13%
3Y*
8.60%
5Y*
5.93%
10Y*
9.81%
ALL TIME*
8.63%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison


PositionAvg. Volume Value (2W)Avg. Volume Value (1M)Avg. Volume Value (3M)
$494.21K$657.50K$547.45K
$1.43B$1.62B$1.62B

PBE vs. XLV - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
PBE
Invesco Dynamic Biotechnology & Genome ETF
10.26%24.84%1.10%3.71%-10.83%1.54%25.66%18.65%-0.19%22.28%
XLV
State Street Health Care Select Sector SPDR ETF
5.90%14.50%2.47%2.07%-2.08%26.04%13.30%20.45%6.28%21.77%

Correlation

The correlation between PBE and XLV is 0.72, which is moderate. They have sometimes moved together and sometimes differently, sharing some price drivers without tracking each other closely.


Correlation
Correlation (1Y)
Focuses on recent behavior, but can change the most.

0.72

Correlation (3Y)
Balances recent behavior with more history.

0.67

Correlation (5Y)
Shows whether the relationship held over a longer period.

0.68

Correlation (10Y)
Provides a long-term view across more market conditions.

0.67

Correlation (All Time)
Calculated using the full available price history since Jun 23, 2005

0.71

The correlation between PBE and XLV has been stable across timeframes, ranging from 0.67 to 0.72 - a consistent structural relationship.

PBE vs. XLV - Sectors Allocation Comparison


Sectors
PBE
XLV

Healthcare

100.0%
99.4%

Financial Services

0.1%

-

Basic Materials

-

-

Communication Services

-

-

Consumer Cyclical

-

-

Consumer Defensive

-

-

Energy

-

-

Industrials

-

-

Real Estate

-

-

Technology

-

0.5%

Utilities

-

-

Healthcare

PBE
100.0%
XLV
99.4%

Financial Services

PBE
0.1%
XLV

-

Basic Materials

PBE

-

XLV

-

Communication Services

PBE

-

XLV

-

Consumer Cyclical

PBE

-

XLV

-

Consumer Defensive

PBE

-

XLV

-

Energy

PBE

-

XLV

-

Industrials

PBE

-

XLV

-

Real Estate

PBE

-

XLV

-

Technology

PBE

-

XLV
0.5%

Utilities

PBE

-

XLV

-

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

PBE vs. XLV — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

PBE
PBE Risk / Return Rank: 8585
Overall Rank
PBE Sharpe Ratio Rank: 8888
Sharpe Ratio Rank
PBE Sortino Ratio Rank: 8989
Sortino Ratio Rank
PBE Omega Ratio Rank: 8484
Omega Ratio Rank
PBE Calmar Ratio Rank: 8787
Calmar Ratio Rank
PBE Martin Ratio Rank: 7676
Martin Ratio Rank

XLV
XLV Risk / Return Rank: 7272
Overall Rank
XLV Sharpe Ratio Rank: 7676
Sharpe Ratio Rank
XLV Sortino Ratio Rank: 8383
Sortino Ratio Rank
XLV Omega Ratio Rank: 7272
Omega Ratio Rank
XLV Calmar Ratio Rank: 7474
Calmar Ratio Rank
XLV Martin Ratio Rank: 5353
Martin Ratio Rank
The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

PBE vs. XLV - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Invesco Dynamic Biotechnology & Genome ETF (PBE) and State Street Health Care Select Sector SPDR ETF (XLV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


PBEXLVDifference
Sharpe ratioReturn per unit of total volatility

+0.41

Sortino ratioReturn per unit of downside risk

+0.41

Omega ratioGain probability vs. loss probability

1.36

1.30

+0.06

Calmar ratioReturn relative to maximum drawdown

3.42

2.57

+0.84

Martin ratioReturn relative to average drawdown

9.57

6.15

+3.42

PBE vs. XLV - Sharpe Ratio Comparison

The current PBE Sharpe Ratio is 2.13, which is comparable to the XLV Sharpe Ratio of 1.72. The chart below compares the historical Sharpe Ratios of PBE and XLV, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

PBE vs. XLV - Drawdown Comparison

The maximum PBE drawdown since its inception was -45.69%, which is greater than XLV's maximum drawdown of -39.17%. Use the drawdown chart below to compare losses from any high point for PBE and XLV.


Loading charts...

Drawdown Indicators


PBEXLVDifference

Max Drawdown

Largest peak-to-trough decline

-45.69%

-39.17%

-6.52%

Max Drawdown (1Y)

Largest decline over 1 year

-11.73%

-10.47%

-1.26%

Max Drawdown (3Y)

Largest decline over 3 years

-22.43%

-17.11%

-5.32%

Max Drawdown (5Y)

Largest decline over 5 years

-34.71%

-17.11%

-17.60%

Max Drawdown (10Y)

Largest decline over 10 years

-37.84%

-28.40%

-9.44%

Current Drawdown

Current decline from peak

-3.83%

-2.82%

-1.01%

Average Drawdown

Average peak-to-trough decline

-16.13%

-7.09%

-9.04%

Ulcer Index

Depth and duration of drawdowns from previous peaks

4.18%

4.37%

-0.19%

Volatility

PBE vs. XLV - Volatility Comparison

The current volatility for Invesco Dynamic Biotechnology & Genome ETF (PBE) is 5.60%, while State Street Health Care Select Sector SPDR ETF (XLV) has a volatility of 6.03%. This indicates that PBE experiences smaller price fluctuations and is considered to be less risky than XLV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


PBEXLVDifference

Volatility (1M)

Calculated over the trailing 1-month period

5.60%

6.03%

-0.43%

Volatility (6M)

Calculated over the trailing 6-month period

13.56%

12.07%

+1.49%

Volatility (1Y)

Calculated over the trailing 1-year period

18.83%

15.90%

+2.93%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

22.50%

15.04%

+7.46%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

24.73%

16.66%

+8.07%

PBE vs. XLV - Expense Ratio Comparison

PBE has a 0.59% expense ratio, which is higher than XLV's 0.08% expense ratio.


Dividends

PBE vs. XLV - Dividend Comparison

PBE's dividend yield for the trailing twelve months is around 1.73%, more than XLV's 1.56% yield.


PositionTTM20252024202320222021202020192018201720162015
PBE
Invesco Dynamic Biotechnology & Genome ETF
1.73%1.00%0.05%0.02%0.00%0.00%0.04%0.00%0.00%0.57%0.38%1.12%
XLV
State Street Health Care Select Sector SPDR ETF
1.56%1.60%1.67%1.59%1.47%1.33%1.49%2.17%1.57%1.47%1.60%1.43%

Frequently Asked Questions


PBE and XLV have a correlation of 0.72, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

XLV has higher volatility (6.03%) compared to PBE (5.60%). In terms of maximum drawdown, PBE dropped -45.69% vs XLV's -39.17%.

On 10-year performance, XLV leads with 9.81% vs 8.19% for PBE. On fees, XLV is cheaper at 0.08% per year. On volatility, PBE has been the lower-risk option at 5.60%. The better choice depends on whether you care most about return, fees, risk, or income.

Over the 10-year period, XLV has performed better with a 9.81% return vs 8.19%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

XLV is cheaper with a 0.08% expense ratio, compared with 0.59% for PBE.

PBE has the higher dividend yield at 1.73%, compared with 1.56% for XLV.

PBE tracks Dynamic Biotech & Genome Intellidex Index (AMEX), while XLV tracks Health Care Select Sector Index. They also come from different issuers: Invesco and State Street. Their fees differ too: 0.59% for PBE and 0.08% for XLV.

PBE currently has the higher Sharpe Ratio (2.13 vs 1.72), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for PBE and XLV

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer